CellVax
Cellvax | Preclinical CRO | Expertise in Oncology and Osteoarthritis.
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 20 % | (26 %) | (83 %) | 413 % | 33 % | - | 80 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 39 % | 38 % | (588 %) | 40 % | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 39 % | 64 % | (451 %) | 47 % | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Cellvax, established in 2001, operates as a preclinical Contract Research Organization (CRO) specializing in oncology and osteoarthritis. The company provides both in vitro and in vivo studies, facilitating the acceleration of drug development processes. Cellvax collaborates with biotech companies, public laboratories, and pharmaceutical societies, offering its expertise and innovative capabilities. The business model is centered around strategic partnerships, allowing for studies in large animal models and participation in European grant funding applications. Cellvax serves clients in the biotech and pharmaceutical sectors, focusing on enhancing research and development efficiency. Keywords: preclinical, CRO, oncology, osteoarthritis, drug development, in vitro, in vivo, biotech, pharmaceutical, collaboration.